Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2024-08-02 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
简式权益变动报告（一）
Major Shareholding Notification Classification · 100% confidence The document is titled "简式权益变动报告书（一）" which translates to "Simplified Equity Change Report (1)". It details the change in shareholding of an individual shareholder (张仁华) in 瑞康医药集团股份有限公司, including the number of shares before and after the transaction, the method of transfer (agreement transfer), the price, and related legal and procedural information. The document references relevant Chinese securities laws and regulations, and includes detailed disclosures about the share transfer agreement, the parties involved, and the impact on the company. This type of document is a notification of a change in major shareholding or equity interest in the company. It is not an annual report, earnings release, or management report, nor is it a proxy statement or voting result announcement. It is a formal disclosure of a significant shareholding change, fitting the category of Major Shareholding Notification (MRQ). The document length and detail confirm it is the report itself, not just an announcement of a report publication or a certification. Therefore, the correct classification is MRQ with high confidence.
2024-08-02 Chinese
简式权益变动报告（二）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书（二）" which translates to a "Simplified Equity Change Report (No. 2)". It details the change in shareholding by an information disclosure obligor (北京岩泉财富投资管理有限公司——岩泉8号私募证券投资基金) acquiring 5.05% of shares in 瑞康医药集团股份有限公司 through an agreement transfer. The document includes detailed information about the parties involved, the share transfer agreement, shareholding before and after the transaction, the purpose of the equity change, and compliance with relevant Chinese securities laws and regulations. It is a formal report disclosing a change in major shareholding. This matches the definition of "Major Shareholding Notification (Code: MRQ)" which is a notification of changes in significant share ownership levels crossing thresholds. The document is not an announcement of a report publication, nor a financial report, nor a regulatory filing of a different nature. Therefore, the correct classification is MRQ with high confidence.
2024-08-02 Chinese
关于公司董事、监事及高管团队增持计划实施完成的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the completion of a share increase plan by the company's directors, supervisors, and senior management team. It details the number of shares acquired, the amount spent, and confirms compliance with relevant laws and regulations. There is no financial report or earnings data presented, nor is it a regulatory certification or a meeting material. The content clearly relates to a transaction involving the company's own shares by insiders (directors and executives). Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on this transaction, supporting this classification with high confidence.
2024-06-24 Chinese
关于拟对外投资设立合资公司的自愿性公告
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by Ruikang Pharmaceutical Group Co., Ltd. regarding its planned external investment to establish a joint venture company. It details the investment overview, parties involved, joint venture company details, investment agreement main contents, purpose and impact of the investment, risk warnings, and reference documents. The document is an announcement about a capital investment and joint venture formation, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data but rather describes a financing and investment activity. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2657 characters, which is consistent with an announcement rather than a full report.
2024-06-14 Chinese
2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2023 annual dividend distribution plan approved at the 2023 Annual General Meeting. It details the dividend amount per share, the record date, the ex-dividend date, and the method of dividend payment. It does not contain full financial statements or comprehensive financial performance data, but rather focuses on the dividend distribution specifics. The document length is short (1927 characters) and it is clearly an announcement of dividend amount and payment details, fitting the definition of a Notice of Dividend Amount (DIV).
2024-05-27 Chinese
2023年年度股东大会的律师见证法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2023 Annual General Meeting (AGM) of 瑞康医药集团股份有限公司. It details the procedures of the AGM, the qualifications of attendees, the agenda items discussed, and the voting results. The document does not contain the actual annual report or financial statements but rather confirms the legality and validity of the AGM process and resolutions passed. It is a legal opinion on the AGM proceedings and voting results, not the AGM materials themselves or the annual report. Therefore, this document fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes and validates the AGM process.
2024-05-21 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.